Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Michelle LeRoux Williams, Ph.D., Elutia’s Chief Scientific Officer, will participate in ...

Integration of clinical and patient-reported outcomes expected to further differentiate EluPro’s utility in cardiac implantable electronic ...

Short interest in Elutia Inc (NASDAQ:ELUT) increased during the last reporting period, rising from 47.25K to 65.03K. This put 0.25% of the company's publicly available shares short. Short interest ...

When NDMA contamination was first discovered in valsartan in 2018, it triggered global recalls, regulatory pressure, and a ...

Elutia’s Roswell facility is FDA-registered as a medical device manufacturing establishment and has not experienced any delays, cost increases, or supplier issues related to the tariffs. The Company ...

Read Our Latest Stock Analysis on UNCY Unicycive Therapeutics Stock Down 12.6 % Shares of UNCY stock opened at $0.52 on Friday. The firm has a market cap of $61.76 million, a price-to-earnings ...

Elutia management will also participate in 1x1 investor meetings. Institutional investors interested in scheduling a meeting may contact an LD Micro or Planet Microcap representative or email IR@ ...

April 04, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia” or the "Company”), a pioneer in drug-eluting biomatrix technologies, today announced that EluPro™, the first ever FDA-cleared ...

Elutia management will also participate in 1x1 investor meetings. Institutional investors interested in scheduling a meeting may contact an LD Micro or Planet Microcap representative or email ...

Elutia management will also participate in 1x1 investor meetings. Institutional investors interested in scheduling a meeting may contact an LD Micro or Planet Microcap representative or email ...